-transparent.png){kind=logo}
OBJECTIVE To compare the antipyretic efficacy of ibuprofen syrup (5 mg/kg per dose) and acetaminophen syrup (10 mg/kg per dose) in children with a history of febrile seizures. METHODS Randomized, multiple-dose, double-blind, cross-over trial. METHODS The outpatient department of a university-affiliated teaching hospital. METHODS Seventy outpatients (mean age, 2.1 years; range, 10 months to 4 years) who had visited the hospital because of a febrile seizure were randomized to treatment at a temperature of 38.5 degrees C or higher. METHODS Study medication was given every 6 hours for 1 to 3 days. Rectal temperatures were recorded at 0, 2, 4, 6, 12, and 24 hours after the first dose. METHODS The temperature 4 hours after the first dose, the mean temperature during treatment, and the highest temperature during treatment were evaluated. Analysis of covariance corrected for the initial temperature, age, weight, and cause of the fever. RESULTS Ibuprofen lowered the initial temperature from 39.1 degrees C to a mean temperature of 37.7 degrees C during treatment; acetaminophen lowered the initial temperature from 39.2 degrees C to 38.0 degrees C. Ibuprofen reduced fever 0.50 degree C more than did acetaminophen at 4 hours (95% confidence interval [CI], -0.98 to -0.02). The mean temperature was 0.26 degree C lower during ibuprofen treatment (95% CI, -0.59 to 0.07); the highest temperature was 0.30 degree C lower (95% CI, -0.73 to 0.13). In 22 patients, a second fever was treated with the opposite medication than the first. In the cross-over analysis, the respective differences were 0.66 degree C (95% CI, -1.29 to -0.06), 0.40 degree C (95% CI, -0.83 to 0.03), and 0.36 degree C (95% CI, -0.81 to 0.08) in favor of ibuprofen. CONCLUSIONS Ibuprofen and acetaminophen are effective antipyretic agents in children with a history of febrile seizures. Ibuprofen yielded significantly greater fever reduction than did acetaminophen 4 hours after the first dose. Research is needed on the value of antipyretic agents for the prevention of febrile seizure recurrence.
A Van Esch, and
H A Van Steensel-Moll, and
E W Steyerberg, and
M Offringa, and
J D Habbema, and
G Derksen-Lubsen
January 2004,
The Annals of pharmacotherapy,
A Van Esch, and
H A Van Steensel-Moll, and
E W Steyerberg, and
M Offringa, and
J D Habbema, and
G Derksen-Lubsen
November 2008,
Clinical pediatrics,
A Van Esch, and
H A Van Steensel-Moll, and
E W Steyerberg, and
M Offringa, and
J D Habbema, and
G Derksen-Lubsen
May 1992,
American journal of diseases of children (1960),
A Van Esch, and
H A Van Steensel-Moll, and
E W Steyerberg, and
M Offringa, and
J D Habbema, and
G Derksen-Lubsen
February 2004,
Pharmacotherapy,
A Van Esch, and
H A Van Steensel-Moll, and
E W Steyerberg, and
M Offringa, and
J D Habbema, and
G Derksen-Lubsen
January 2011,
Jornal de pediatria,
A Van Esch, and
H A Van Steensel-Moll, and
E W Steyerberg, and
M Offringa, and
J D Habbema, and
G Derksen-Lubsen
October 2017,
Clinical pediatrics,
A Van Esch, and
H A Van Steensel-Moll, and
E W Steyerberg, and
M Offringa, and
J D Habbema, and
G Derksen-Lubsen
August 2019,
Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies,
A Van Esch, and
H A Van Steensel-Moll, and
E W Steyerberg, and
M Offringa, and
J D Habbema, and
G Derksen-Lubsen
November 1997,
The Journal of pediatrics,
A Van Esch, and
H A Van Steensel-Moll, and
E W Steyerberg, and
M Offringa, and
J D Habbema, and
G Derksen-Lubsen
January 1985,
The British journal of clinical practice,
A Van Esch, and
H A Van Steensel-Moll, and
E W Steyerberg, and
M Offringa, and
J D Habbema, and
G Derksen-Lubsen
July 1989,
Clinical pharmacology and therapeutics,
